K2M
Develops and commercializes complex spine and minimally invasive surgical solutions, including 3D-printed titanium spinal implants (e.g., CASCADIA, MOJAVE PL 3D) using Lamellar 3D Titanium technology, reducing surgical complexity and improving patient outcomes.
- CEO / Founder
- Eric Major
- Team Size
- 201-500
- Stage
- Acquired
- Total Funding
- $132M
- Latest Round
- IPO
- Key Investors
- Welsh, Carson, Anderson & Stowe
Technology & Products
Key Products
CASCADIA Interbody Systems; MOJAVE PL 3D Expandable Interbody; CAPRI Small 3D Static Corpectomy Cage; Balance ACS Platform; Deformity Correction Systems; Spinal Stabilization Systems; Lateral Access Systems; Minimally Invasive Systems; Cervical Plates
Technological Advantage
Proprietary Lamellar 3D Titanium technology enables the production of 3D-printed spinal implants with enhanced osseointegration properties, protected by a portfolio of 415 patents issued in FY2016. This technology is integrated into a broad product portfolio, creating switching costs for surgeons and hospitals.
Differentiation
Value Proposition
Provides innovative 3D-printed spinal implants that enhance osseointegration and surgical efficiency, reducing procedure time and improving patient recovery, while offering a comprehensive portfolio for complex spine cases.
How They Differentiate
K2M differentiates through its proprietary Lamellar 3D Titanium technology and first-to-market 3D-printed expandable implants, offering superior osseointegration compared to traditional PEEK or titanium-coated devices from competitors.
Market & Competition
Target Customers
Spine surgeons, hospitals, and healthcare providers
Industry Verticals
Medical Devices; Spine Surgery
Competitors
Medtronic Spine and Biologics; DePuy Synthes; Globus Medical; NuVasive; Stryker
Growth & Milestones
Growth Metrics
Revenue reached $100M+; acquired by Stryker for $1.4B in 2018
Major Milestones
Founded in 2004; IPO in 2014 raising ~$132M; FDA clearance of CASCADIA Interbody Systems in 2016; FDA clearance of MOJAVE PL 3D Expandable Interbody in 2018; Acquired by Stryker for $1.4B in 2018
Notable Customers
Hospital for Special Surgery; Cleveland Clinic; Mayo Clinic; Johns Hopkins Hospital; UCLA Health